GlassScriptPhysician profile
Suresh Mukkamala
NPI 1770973398
$2,189.21
in general payments reported to CMS, 2019-2025
28 companies · $557 in 2025
The $557 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $738 · 2020: $279 · 2021: $146 · 2022: $47.90 · 2023: $26.44 · 2024: $395 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $863 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $863.32 |
| Education | $115.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $339.38 | 2019-2025 | Keytruda |
| Jazz Pharmaceuticals INC. | $259.04 | 2020 | |
| Medtronic USA, INC. | $195.30 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $125.49 | 2019 | |
| Novo Nordisk INC | $121.23 | 2019 | |
| Incyte Corporation | $113.69 | 2025 | Jakafi |
| Novartis Pharmaceuticals Corporation | $111.54 | 2024-2025 | |
| Astellas Pharma US INC | $99.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $91.25 | 2024-2025 | Enhertu |
| Celgene Corporation | $87.23 | 2019-2024 | Reblozyl |
| Beone Medicines USA, INC. | $83.82 | 2025 | Tevimbra, Brukinsa |
| Janssen Biotech, INC. | $83.04 | 2022-2025 | Darzalex, Tecvayli |
| Daiichi Sankyo INC. | $76.24 | 2024-2025 | Enhertu, Datroway, Vanflyta |
| Glaxosmithkline, LLC. | $76.06 | 2025 | Ojjaara, Jemperli |
| Pfizer INC. | $35.45 | 2024-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $31.14 | 2024 | Epkinly |
| Cti Biopharma Corp. | $26.44 | 2023 | Vonjo |
| Takeda Pharmaceuticals U.S.A., INC. | $25.68 | 2025 | Fruzaqla |
| Springworks Therapeutics, INC. | $25.01 | 2024 | Ogsiveo |
| Beigene USA, INC. | $23.94 | 2024 | Tevimbra |
| Abbvie INC. | $23.44 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $23.08 | 2021 | |
| Gilead Sciences, INC. | $22.71 | 2024 | |
| Sumitomo Pharma America, INC. | $21.93 | 2024 | Orgovyx |
| Sobi, INC | $18.46 | 2024 | |
| Kite Pharma, INC. | $17.01 | 2025 | Yescarta |
| Array Biopharma INC | $16.38 | 2024 | Braftovi, Xalkori, Lorbrena |
| Ipsen Biopharmaceuticals, INC | $16.23 | 2024 | Onivyde |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suresh Mukkamala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.